Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX) is a biotechnology company centered on DehydraTECH™, a patented oral drug delivery formulation and processing platform. Company news releases highlight ongoing research and development programs where DehydraTECH is evaluated with active pharmaceutical ingredients such as GLP-1 drugs and cannabidiol (CBD), as well as updates on licensing, partnerships and capital markets activity.
Investors following LEXX news can expect detailed coverage of clinical and preclinical study results, particularly in the GLP-1 sector. Recent announcements describe human pilot studies and a registered Phase 1b study in Australia that compare DehydraTECH-based oral formulations of semaglutide, tirzepatide and liraglutide against existing injectable or oral reference products. These updates often include information on safety, tolerability, adverse events, blood glucose and HbA1c changes, body weight, biodistribution and blood pressure outcomes.
Lexaria’s news flow also includes strategic and business development updates, such as the extension of a Material Transfer Agreement with a pharmaceutical company evaluating DehydraTECH, the engagement of a global life science business development advisory firm, and commentary on how new data sets are being used to guide future R&D plans. In addition, the company regularly reports on financing transactions via registered direct offerings and private placements, describing how proceeds are intended to support research, working capital and general corporate purposes.
For readers tracking LEXX, this news page provides a centralized view of the company’s scientific progress, intellectual property developments, partnership discussions and funding activities related to its DehydraTECH platform.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the granting of its 24th patent, titled "Compositions Infused with Nicotine Compounds and Methods of Use Thereof," enhancing its global intellectual property portfolio. This Australian patent allows the use of DehydraTECH technology for various nicotine forms, potentially increasing product value. Previous studies show DehydraTECH delivers nicotine significantly faster than conventional methods. Additionally, the company issued 36,700 stock options to staff at an exercise price of $3.39.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) reported significant findings from an animal study evaluating its DehydraTECH formulation of sildenafil, showing a 74% increase in drug delivery at 4 minutes compared to a generic control. The study indicated a 70% higher maximum concentration (Cmax) and a 37% improvement in total delivery (AUC). Results showed potential for developing faster-acting sildenafil formulations. However, improvements did not achieve statistical significance, necessitating further studies.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) shared an annual letter from CEO Chris Bunka, highlighting successes and strategic directions for the company. The focus remains on advancing the DehydraTECH drug delivery technology, aimed at overcoming industry inertia and regulatory challenges. Lexaria reported a growth in shareholder base, with average shares owned by NOBO shareholders increasing by 216% in 2021. The company's institutional ownership has also surged, ranging between 9% and 16%. The aim is to leverage this momentum for potential regulatory and commercial success in 2022.
Lexaria Bioscience Corp. (NASDAQ:LEXX) recently highlighted a study demonstrating cannabinoids' potential to inhibit SARS-CoV-2 infection.
Dr. Richard van Breeman noted that oral delivery of cannabinoids is recommended over smoking or vaping for effectiveness.
Lexaria's DehydraTECH™ technology enhances cannabinoid delivery, with applications in therapeutic formulations.
The study found cannabinoid acids can block cellular entry of the virus, presenting significant implications for treatment strategies.
Lexaria holds a strong patent portfolio, with ongoing research into pharmaceutical applications.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has received early Independent Review Board approval for its DehydraTECH-CBD hypertension study, HYPER-H21-4, scheduled to begin dosing by April 2022. This study, funded through existing cash resources, aims to assess the treatment's efficacy in reducing blood pressure among 60 volunteers aged 45-70. The $28 billion hypertension market presents significant growth potential, especially in emerging economies. With a comprehensive analysis including blood pressure monitoring and brain imaging, Lexaria seeks to validate DehydraTECH-CBD as a promising anti-hypertensive therapy.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced a media and digital marketing agreement with SRAX to enhance investor engagement over the next year. This follows substantial progress made by the company in 2021, with plans for an extensive 2022 including a human hypertension study and a nicotine study. Lexaria will issue 224,299 restricted shares valued at $1.2 million to SRAX for its services. The agreement aims to maximize visibility through a sustained marketing campaign, leveraging SRAX's analytical capabilities.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announces the near completion of its human clinical study HYPER-H21-3, which is exploring the effects of DehydraTECH-CBD on acute pulmonary hypertension. The study involved a placebo-controlled trial with 16 volunteers receiving a 300mg dose of DehydraTECH-CBD. Blood samples are currently being analyzed, with results expected soon. This research aims to contribute to the understanding of DehydraTECH-CBD as a treatment for hypertension and will be submitted to the FDA as part of their investigational drug research program.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has released follow-up results from clinical study HYPER-H21-2, indicating that its DehydraTECH-CBD significantly reduces arterial stiffness after just one day of dosing. This finding suggests potential applications beyond hypertension, including in cardiovascular health. Notably, pulse wave velocity (PWV) was measured at 8.1 ± 0.3 m/s for DehydraTECH-CBD versus 8.3 ± 0.3 m/s for placebo, with all comparisons yielding statistically significant results (p < 0.01). Future studies, including the upcoming HYPER-H21-4, will explore these findings further.
Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) announces ambitious R&D plans for 2022, focusing on its DehydraTECH platform. Key studies include an investigation into heart disease and hypertension, as well as oral nicotine delivery alternatives. With funding of approximately USD$15 million secured, Lexaria aims to enhance drug delivery for treatments including dementia, rheumatoid disease, and diabetes. The company is debt-free and expects its cash reserves to sustain operations until at least Q2 2023. Strategic partnerships are planned post-data generation.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has announced a new hypertension study, HYPER-H21-4, aimed at evaluating its DehydraTECH-CBD. This ambitious study involves 60 participants aged 45-70 and aims to gather data over six weeks, assessing various health metrics. Positive results could aid regulatory approval for DehydraTECH-CBD as a hypertension treatment. Additionally, updates on three ongoing studies show promising potential in blood pressure reduction. The global hypertension market represents a significant opportunity, valued at $28 billion annually.